Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis
JAMA · 21.01.2025 · 333 (3) · 213
DOI: 10.1001/jama.2024.22730 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA, erschienen am 21.01.2025. Verfasst von Krithika Loganath und 46 weiteren Autor:innen. Beteiligte Einrichtung: British Heart Foundation Centre of Research Excellence, University of Edinburgh, Edinburgh, Scotland. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Heart Valve Prosthesis Implantation, Myocardium, Transcatheter Aortic Valve Replacement. Die Arbeit wurde bisher 167-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: British Heart Foundation.
Abstract (Originalsprache)
Importance Development of myocardial fibrosis in patients with aortic stenosis precedes left ventricular decompensation and is associated with an adverse long-term prognosis.
Objective
To investigate whether early valve intervention reduced the incidence of all-cause death or unplanned aortic stenosis–related hospitalization in asymptomatic patients with severe aortic stenosis and myocardial fibrosis. Design, Setting, and Participants This prospective, randomized, open-label, masked end point trial was conducted between August 2017 and October 2022 at 24 cardiac centers across the UK and Australia. Asymptomatic patients with severe aortic stenosis and myocardial fibrosis were included. The final date of follow-up was July 26, 2024 Intervention Early valve intervention with transcatheter or surgical aortic valve replacement or guideline-directed conservative management. Main Outcomes and Measures The primary outcome was a composite of all-cause death or unplanned aortic stenosis–related hospitalization in a time-to-first-event intention-to-treat analysis. There were 9 secondary outcomes, including the components of the primary outcome and symptom status at 12 months.
Results
The trial enrolled 224 eligible patients (mean [SD] age, 73 [9] years; 63 women [28%]; mean [SD] aortic valve peak velocity of 4.3 [0.5] m/s) of the originally planned sample size of 356 patients. The primary end point occurred in 20 of 113 patients (18%) in the early intervention group and 25 of 111 patients (23%) in the guideline-directed conservative management group (hazard ratio, 0.79 [95% CI, 0.44-1.43]; P = .44; between-group difference, −4.82% [95% CI, −15.31% to 5.66%]). Of 9 prespecified secondary end points, 7 showed no significant difference. All-cause death occurred in 16 of 113 patients (14%) in the early intervention group and 14 of 111 (13%) in the guideline-directed group (hazard ratio, 1.22 [95% CI, 0.59-2.51]) and unplanned aortic stenosis hospitalization occurred in 7 of 113 patients (6%) and 19 of 111 patients (17%), respectively (hazard ratio, 0.37 [95% CI, 0.16-0.88]). Early intervention was associated with a lower 12-month rate of New York Heart Association class II-IV symptoms than guideline-directed conservative management (21 [19.7%] vs 39 [37.9%]; odds ratio, 0.37 [95% CI, 0.20-0.70]). Conclusions and Relevance In asymptomatic patients with severe aortic stenosis and myocardial fibrosis, early aortic valve intervention had no demonstrable effect on all-cause death or unplanned aortic stenosis–related hospitalization. The trial had a wide 95% CI around the primary end point, with further research needed to confirm these findings. Trial Registration ClinicalTrials.gov Identifier: NCT03094143
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- British Heart Foundation Centre of Research Excellence, University of Edinburgh, Edinburgh, Scotland.
- Edinburgh Heart Centre, Royal Infirmary of Edinburgh, Edinburgh, Scotland.
- Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
- Department of Cardiology, Norfolk and Norwich University Hospital, Norwich, United Kingdom.
- Department of Coronary Disease and Heart Failure, Jagiellonian University Medical College, Krakow, Poland.
- University of Medicine and Pharmacy Carol Davila, Cardiology Department, Euroecholab, Bucharest, Romania.
Förderung
- British Heart Foundation
Zitieren
APA
Loganath, K., Craig, N. J., Everett, R. J., Bing, R., Tsampasian, V., Molek, P., Botezatu, S., Aslam, S., Lewis, S., Graham, C., White, A. C., MacGillivray, T., Tuck, C. E., Rayson, P., Cranley, D., Irvine, S., Armstrong, R., Milne, L., Chin, C. W. L., …, & EVOLVED investigators (2025). Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis. JAMA, 333(3), 213. https://doi.org/10.1001/jama.2024.22730
Vancouver
Loganath K, Craig NJ, Everett RJ, Bing R, Tsampasian V, Molek P, et al. Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis. JAMA. 2025;333(3):213. doi:10.1001/jama.2024.22730
BibTeX
@article{Loganath2025,
author = {Loganath, Krithika and Craig, Neil J and Everett, Russell J and Bing, Rong and Tsampasian, Vasiliki and Molek, Patrycja and Botezatu, Simona and Aslam, Saadia and Lewis, Steff and Graham, Catriona and White, Audrey C and MacGillivray, Tom and Tuck, Christopher E and Rayson, Phillip and Cranley, Denise and Irvine, Sian and Armstrong, Ruth and Milne, Lynsey and Chin, Calvin W L and Hillis, Graham S and Fairbairn, Timothy and Greenwood, John P and Steeds, Richard and Leslie, Stephen J and Lang, Chim C and Bucciarelli-Ducci, Chiara and Joshi, Nikhil V and Kunadian, Vijay and Vassiliou, Vassilios S and Dungu, Jason N and Hothi, Sandeep S and Boon, Nicholas and Prasad, Sanjay K and Keenan, Niall G and Dawson, Dana and Treibel, Thomas A and Motwani, Mani and Miller, Christopher A and Mills, Nicholas L and Rajani, Ronak and Ripley, David P and McCann, Gerry P and Prendergast, Bernard and Singh, Anvesha and Newby, David E and Dweck, Marc R and EVOLVED investigators, EVOLVED investigators},
title = {Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis},
journal = {JAMA},
year = {2025},
volume = {333},
number = {3},
pages = {213},
doi = {10.1001/jama.2024.22730}
}
EUVIMED